118 related articles for article (PubMed ID: 23302073)
21. Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol.
Luckey CJ; King GM; Marto JA; Venketeswaran S; Maier BF; Crotzer VL; Colella TA; Shabanowitz J; Hunt DF; Engelhard VH
J Immunol; 1998 Jul; 161(1):112-21. PubMed ID: 9647214
[TBL] [Abstract][Full Text] [Related]
22. A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity.
Armandola EA; Momburg F; Nijenhuis M; Bulbuc N; Früh K; Hämmerling GJ
Eur J Immunol; 1996 Aug; 26(8):1748-55. PubMed ID: 8765016
[TBL] [Abstract][Full Text] [Related]
23. Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA Class I expression in type I diabetic cells.
Wang F; Li X; Annis B; Faustman DL
Hum Gene Ther; 1995 Aug; 6(8):1005-17. PubMed ID: 7578413
[TBL] [Abstract][Full Text] [Related]
24. Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport.
Fruci D; Lauvau G; Saveanu L; Amicosante M; Butler RH; Polack A; Ginhoux F; Lemonnier F; Firat H; van Endert PM
J Immunol; 2003 Mar; 170(6):2977-84. PubMed ID: 12626550
[TBL] [Abstract][Full Text] [Related]
25. An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL.
Hammond SA; Johnson RP; Kalams SA; Walker BD; Takiguchi M; Safrit JT; Koup RA; Siliciano RF
J Immunol; 1995 Jun; 154(11):6140-56. PubMed ID: 7538543
[TBL] [Abstract][Full Text] [Related]
26. CD8+ T cell responses against TAP-inhibited cells are readily detected in the human population.
Lampen MH; Verweij MC; Querido B; van der Burg SH; Wiertz EJ; van Hall T
J Immunol; 2010 Dec; 185(11):6508-17. PubMed ID: 20980626
[TBL] [Abstract][Full Text] [Related]
27. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma.
Agrawal S; Reemtsma K; Bagiella E; Oluwole SF; Braunstein NS
Cell Immunol; 2004 Apr; 228(2):130-7. PubMed ID: 15219464
[TBL] [Abstract][Full Text] [Related]
28. IFN-gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase.
Sewell AK; Price DA; Teisserenc H; Booth BL; Gileadi U; Flavin FM; Trowsdale J; Phillips RE; Cerundolo V
J Immunol; 1999 Jun; 162(12):7075-9. PubMed ID: 10358150
[TBL] [Abstract][Full Text] [Related]
29. Exploring the minimal functional unit of the transporter associated with antigen processing.
Koch J; Guntrum R; Tampé R
FEBS Lett; 2005 Aug; 579(20):4413-6. PubMed ID: 16061226
[TBL] [Abstract][Full Text] [Related]
30. Tumor surveillance: expression of the transporter associated with antigen processing (TAP-1) in ex-vivo human tumor samples and its elevation by in vitro treatment with IFN-gamma and TNF-alpha.
Nagy N; Vánky F; Klein E
Immunol Lett; 1998 Dec; 64(2-3):153-60. PubMed ID: 9870667
[TBL] [Abstract][Full Text] [Related]
31. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions.
Vitale M; Rezzani R; Rodella L; Zauli G; Grigolato P; Cadei M; Hicklin DJ; Ferrone S
Cancer Res; 1998 Feb; 58(4):737-42. PubMed ID: 9485029
[TBL] [Abstract][Full Text] [Related]
32. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens.
Seidel UJ; Oliveira CC; Lampen MH; Hall Tv
Cancer Immunol Immunother; 2012 Jan; 61(1):119-25. PubMed ID: 22116347
[TBL] [Abstract][Full Text] [Related]
33. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
34. Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope.
Wölfel C; Drexler I; Van Pel A; Thres T; Leister N; Herr W; Sutter G; Huber C; Wölfel T
Int J Cancer; 2000 Nov; 88(3):432-8. PubMed ID: 11054673
[TBL] [Abstract][Full Text] [Related]
35. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.
Raafat N; Sadowski-Cron C; Mengus C; Heberer M; Spagnoli GC; Zajac P
Int J Cancer; 2012 Sep; 131(5):E659-69. PubMed ID: 22116674
[TBL] [Abstract][Full Text] [Related]
36. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer.
Chen HL; Gabrilovich D; Tampé R; Girgis KR; Nadaf S; Carbone DP
Nat Genet; 1996 Jun; 13(2):210-3. PubMed ID: 8640228
[TBL] [Abstract][Full Text] [Related]
37. Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line.
Alpan RS; Zhang M; Pardee AB
Cancer Res; 1996 Oct; 56(19):4358-61. PubMed ID: 8813124
[TBL] [Abstract][Full Text] [Related]
38. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.
Seliger B; Ritz U; Abele R; Bock M; Tampé R; Sutter G; Drexler I; Huber C; Ferrone S
Cancer Res; 2001 Dec; 61(24):8647-50. PubMed ID: 11751378
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.
Andersen MH; Bonfill JE; Neisig A; Arsequell G; Sondergaard I; Valencia G; Neefjes J; Zeuthen J; Elliott T; Haurum JS
J Immunol; 1999 Oct; 163(7):3812-8. PubMed ID: 10490979
[TBL] [Abstract][Full Text] [Related]
40. Vaccination and the TAP-independent antigen processing pathways.
López D; Lorente E; Barriga A; Johnstone C; Mir C
Expert Rev Vaccines; 2013 Sep; 12(9):1077-83. PubMed ID: 24053400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
